Turn Therapeutics Inc. (TTRX) Stock Analysis and Metrics

Turn Therapeutics

NASDAQ: TTRX

$8.54 ▼ -0.94 (-9.92%)

At close: Jul 24, 2026 · 4:00 PM UTC

Financial Ratios

Market Cap253.20 Mn

P/E-17.80

Div. Yield0.00

Total Debt (Qtr)5.94 Mn

Add ratio to table…

About

Turn Therapeutics is a clinical-stage biopharmaceutical company focused on developing non-systemic, non-biologic topical immunomodulators for inflammatory skin diseases and fungal infections. The company’s lead asset, GX-03, targets moderate-to-severe eczema and onychomycosis, leveraging a proprietary formulation of polyhexanide (PHMB) with demonstrated anti-inflammatory and antimicrobial properties. Turn Therapeutics also explores a thermostable intranasal vaccine platform, though its primary efforts remain centered on dermatology. The company operates with a capital-efficient model, outsourcing manufacturing and leveraging partnerships to advance its pipeline while minimizing fixed costs.

Turn Therapeutics generates revenue through licensing agreements and milestone payments tied to its medical device portfolio. Its historical device clearances, including K183681, K160872, and K171191, have been licensed to commercial partners such as Medline, providing passive income streams. The company also earns royalties from partnerships, including a $1.0 million upfront payment and potential future milestones of up to $69.55 million from MiMedx for the FleX Product. While drug development remains the core focus, these agreements fund clinical progress without requiring significant capital investment.

The company operates through the following segments:

• Dermatology Drug Development: This segment drives the clinical advancement of GX-03 for eczema and onychomycosis. GX-03 is currently in a Phase 2 trial for moderate-to-severe eczema, with topline results expected in mid-2026. The program leverages PHMB’s dual mechanism of action, targeting inflammatory cytokines and microbial burden without systemic absorption. For onychomycosis, GX-03 has shown nail penetration and antifungal activity in preclinical studies, positioning it as a potential alternative to existing topical and oral therapies.

• Medical Device Licensing: This segment monetizes FDA-cleared medical devices through partnerships. Products like K183681, a porous antimicrobial gauze, and K171191, indicated for dermatitis management, have been licensed to Medline and other distributors. These devices provide real-world tolerability data for the GX-03 formula while generating licensing fees and royalties. The company retains rights to explore additional device applications but prioritizes drug development.

• Exploratory Vaccine Platform: This segment focuses on the PermaFusion suspension platform, designed to enhance the stability of live vaccines for intranasal delivery. Early data demonstrated 100% recovery of a live VSV vaccine vector after 14 days at ambient temperature, suggesting potential for needle-free, thermostable vaccines. While still in preclinical stages, this program targets government and military procurement opportunities, with initial applications in influenza.

Turn Therapeutics competes in the dermatology and antifungal markets, where established players dominate with systemic and biologic therapies. Key competitors in eczema include Dupixent (dupilumab), an injectable biologic, and topical JAK inhibitors like Vtama. For onychomycosis, oral terbinafine (Lamisil) and topical efinaconazole (Jublia) lead the market but face limitations in efficacy and safety. Turn Therapeutics differentiates itself through GX-03’s non-systemic, non-biologic approach, which avoids the side effects of steroids, biologics, and oral antifungals. Its proprietary PermaFusion platform also enables superior nail penetration and cytokine modulation, addressing unmet needs in topical therapies. The company’s lean operating model and partnerships further enhance its competitive positioning by reducing development costs and accelerating commercialization.

Turn Therapeutics serves a diverse customer base across its segments. For medical devices, its primary customers include large distributors like Medline and MiMedx, which commercialize products in wound care and dermatology. In drug development, the company targets patients with moderate-to-severe eczema and onychomycosis, particularly those seeking non-steroidal, non-injectable alternatives. Its exploratory vaccine platform aims to supply government agencies, military organizations, and public health entities, such as BARDA and the World Health Organization, with thermostable, needle-free vaccines. The company also collaborates with contract research organizations and manufacturing partners to advance its pipeline.

Investment Thesis

▲ Bull case

Turn Therapeutics is positioned to capitalize on a significant unmet need in the atopic dermatitis market, where current therapies often come with systemic side effects or limited long-term efficacy, creating a clear opportunity for GX-03 as a first-in-class topical therapy targeting upstream inflammatory pathways like IL-36 and IL-31 without systemic suppression. The interim Phase 2 data showing 92.6% of GX-03-treated subjects achieving EASI-50 at Week 4 versus 65.2% for vehicle, along with improving EASI-90 rates over time, indicates not just efficacy but a rapid onset of action that could differentiate it in a crowded market where speed of symptom relief is a key patient and physician priority. This early and deepening response profile suggests GX-03 may achieve meaningful clinical endpoints sooner than anticipated, potentially supporting an accelerated regulatory pathway or label expansion beyond moderate-to-severe cases if trends hold in the full trial.
The company’s strategic appointments of former FDA Commissioner Stephen Hahn and former CDC Director Robert Redfield provide tangible, high-impact advantages in navigating regulatory and public health landscapes that are often underestimated by the market, particularly for a novel mechanism like GX-03’s upstream cytokine modulation. Hahn’s direct involvement in guiding clinical and regulatory strategy for GX-03, combined with Redfield’s expertise in public health policy and translational science, significantly derisks the path to FDA interactions and potential accelerated approval pathways, especially as the company prepares for mid-2026 topline data and subsequent regulatory engagements. This level of former agency leadership on the advisory team is rare for a clinical-stage biotech and could streamline IND-enabling activities, endpoint alignment, and post-trial submissions in ways that reduce both time and cost to market.
The expansion into a thermostable intranasal influenza vaccine using Turn’s PermaFusion® platform represents a de-risked, near-term catalyst that diversifies revenue potential beyond GX-03 while leveraging existing technology, with in-vivo and in-vitro studies slated to begin in Q1 2026 — a timeline that could yield preliminary data by mid-year, creating multiple inflection points in a single fiscal year. This move expands the company’s addressable market into infectious disease preparedness, a sector with growing governmental and private investment, and positions Turn to potentially access non-dilutive funding or BARDA-style contracts, which are not currently reflected in market expectations focused solely on dermatology. The ability to repurpose its core delivery technology for pandemic-ready vaccines adds optionality that could significantly enhance long-term valuation if even one additional program advances.
The strategic partnership with Medline, a global leader in wound care and healthcare distribution, provides a clear and underappreciated path to near-term revenue generation in late 2026 through the commercialization of PermaFusion®-based wound care products, which validates the platform’s utility beyond GX-03 and creates a recurring revenue stream independent of dermatology trial outcomes. This partnership is not merely a supply agreement but a co-development and commercialization effort that leverages Medline’s extensive institutional sales force and global reach, meaning Turn could begin recognizing revenue while still awaiting GX-03 topline data — a critical de-risking factor that extends the company’s runway beyond current expectations and supports continued investment in clinical programs without immediate dilution pressure.
The recent $25 million growth capital facility from Avenue Capital Group, with an initial $7 million tranche already funded and the remainder tied to clinical and corporate milestones, provides non-dilutive runway extension through the end of 2027, far exceeding typical cash runway expectations for a clinical-stage biotech and allowing the company to fund both the GX-03 Phase 2 readout and preparatory work for registrational trials without rushing into a dilutive equity raise. This structure aligns investor incentives with clinical success, meaning the company is unlikely to face funding gaps during critical inflection points like the mid-2026 topline data release, and the milestone-based tranches encourage disciplined execution — a factor that reduces execution risk and supports sustained progress toward value-creating events.

Turn Therapeutics is positioned to capitalize on a significant unmet need in the atopic dermatitis market, where current therapies often come with systemic side effects or limited long-term efficacy, creating a clear opportunity for GX-03 as a first-in-class topical therapy targeting upstream inflammatory pathways like IL-36 and IL-31 without systemic suppression. The interim Phase 2 data showing 92.6% of GX-03-treated subjects achieving EASI-50 at Week 4 versus 65.2% for vehicle, along with improving EASI-90 rates over time, indicates not just efficacy but a rapid onset of action that could differentiate it in a crowded market where speed of symptom relief is a key patient and physician priority. This early and deepening response profile suggests GX-03 may achieve meaningful clinical endpoints sooner than anticipated, potentially supporting an accelerated regulatory pathway or label expansion beyond moderate-to-severe cases if trends hold in the full trial.
The company’s strategic appointments of former FDA Commissioner Stephen Hahn and former CDC Director Robert Redfield provide tangible, high-impact advantages in navigating regulatory and public health landscapes that are often underestimated by the market, particularly for a novel mechanism like GX-03’s upstream cytokine modulation. Hahn’s direct involvement in guiding clinical and regulatory strategy for GX-03, combined with Redfield’s expertise in public health policy and translational science, significantly derisks the path to FDA interactions and potential accelerated approval pathways, especially as the company prepares for mid-2026 topline data and subsequent regulatory engagements. This level of former agency leadership on the advisory team is rare for a clinical-stage biotech and could streamline IND-enabling activities, endpoint alignment, and post-trial submissions in ways that reduce both time and cost to market.
The expansion into a thermostable intranasal influenza vaccine using Turn’s PermaFusion® platform represents a de-risked, near-term catalyst that diversifies revenue potential beyond GX-03 while leveraging existing technology, with in-vivo and in-vitro studies slated to begin in Q1 2026 — a timeline that could yield preliminary data by mid-year, creating multiple inflection points in a single fiscal year. This move expands the company’s addressable market into infectious disease preparedness, a sector with growing governmental and private investment, and positions Turn to potentially access non-dilutive funding or BARDA-style contracts, which are not currently reflected in market expectations focused solely on dermatology. The ability to repurpose its core delivery technology for pandemic-ready vaccines adds optionality that could significantly enhance long-term valuation if even one additional program advances.
The strategic partnership with Medline, a global leader in wound care and healthcare distribution, provides a clear and underappreciated path to near-term revenue generation in late 2026 through the commercialization of PermaFusion®-based wound care products, which validates the platform’s utility beyond GX-03 and creates a recurring revenue stream independent of dermatology trial outcomes. This partnership is not merely a supply agreement but a co-development and commercialization effort that leverages Medline’s extensive institutional sales force and global reach, meaning Turn could begin recognizing revenue while still awaiting GX-03 topline data — a critical de-risking factor that extends the company’s runway beyond current expectations and supports continued investment in clinical programs without immediate dilution pressure.
The recent $25 million growth capital facility from Avenue Capital Group, with an initial $7 million tranche already funded and the remainder tied to clinical and corporate milestones, provides non-dilutive runway extension through the end of 2027, far exceeding typical cash runway expectations for a clinical-stage biotech and allowing the company to fund both the GX-03 Phase 2 readout and preparatory work for registrational trials without rushing into a dilutive equity raise. This structure aligns investor incentives with clinical success, meaning the company is unlikely to face funding gaps during critical inflection points like the mid-2026 topline data release, and the milestone-based tranches encourage disciplined execution — a factor that reduces execution risk and supports sustained progress toward value-creating events.

▼ Bear case

Turn Therapeutics remains a pre-revenue clinical-stage company with no approved products, and despite promising interim Phase 2 data for GX-03 in atopic dermatitis, the therapy has not yet demonstrated efficacy in a pivotal trial, meaning the current valuation may be pricing in success that is far from guaranteed, particularly given the high failure rate in dermatology drug development where even strong Phase 2 signals often fail to replicate in larger, more diverse Phase 3 populations. The interim analysis was based on only 50 subjects — a small subset of the planned trial — and while the EASI-50 and EASI-90 responses are encouraging, they lack the statistical power and durability data needed to confidently predict Phase 3 outcomes, especially in a disease as heterogeneous as atopic dermatitis where placebo response rates can be high and transient improvements common.
The company’s reliance on a novel mechanism — upstream modulation of epithelial danger sensing and cytokine signaling via polyhexanide — introduces significant regulatory and scientific uncertainty, as there are no approved topical therapies with this exact mechanism of action, meaning the FDA may require extensive mechanistic data, long-term safety studies, or additional clinical validation beyond what is currently planned, potentially delaying approval or requiring a larger trial footprint than anticipated. Unlike biologics targeting specific cytokines (e.g., dupilumab), GX-03’s broad upstream effects could raise questions about off-target effects on skin microbiome or barrier function over time, and the lack of precedent may lead to prolonged regulatory scrutiny, especially if the agency classifies it as a combination product or requests additional non-clinical toxicology data.
While the expansion into an intranasal influenza vaccine leverages Turn’s PermaFusion® platform, this represents a significant strategic shift into a highly competitive and capital-intensive vaccine market where success depends not only on preclinical data but on complex manufacturing, cold chain logistics (despite claims of thermostability), and proven immunogenicity in humans — none of which have been demonstrated yet, and the company has no prior experience in vaccine development or regulatory pathways for infectious disease candidates. The vaccine space is littered with failures from companies that overestimated platform transferability, and without partnerships with established vaccinologists or BARDA engagement, this initiative may consume valuable R&D resources without generating near-term value, diverting focus from the core GX-03 program at a critical juncture.
The Medline partnership, while promising for future wound care revenue, remains contingent on successful product development, regulatory clearance for PermaFusion® in wound indications, and commercial adoption — none of which are guaranteed, and the company has not yet disclosed any preclinical or clinical data supporting PermaFusion®’s efficacy in wound healing, infection control, or exudate management, meaning the near-term revenue expectations for late 2026 are highly speculative. Wound care is a crowded market with entrenched players and stringent reimbursement hurdles, and without demonstrated clinical superiority or cost-saving data, Turn may struggle to gain traction even if the product clears regulatory bars, making the revenue timeline uncertain and potentially delayed beyond current guidance.
Turn Therapeutics’ financials reveal a structural imbalance: operating expenses are heavily weighted toward general and administrative costs ($5.6 million in 2025 vs. $265,000 in R&D), suggesting that a disproportionate amount of capital is being spent on infrastructure, investor relations, and corporate overhead rather than direct therapeutic development, which could slow clinical progress despite the cash runway extensions. This imbalance, combined with a net loss that widened from $1.8 million in 2024 to $3.2 million in 2025 — driven largely by a quadrupling of G&A expenses — indicates that scaling as a public company may be consuming resources at a rate that undermines the efficiency of its R&D spend, raising concerns about whether the company can maintain fiscal discipline while advancing multiple pipelines simultaneously.

Turn Therapeutics remains a pre-revenue clinical-stage company with no approved products, and despite promising interim Phase 2 data for GX-03 in atopic dermatitis, the therapy has not yet demonstrated efficacy in a pivotal trial, meaning the current valuation may be pricing in success that is far from guaranteed, particularly given the high failure rate in dermatology drug development where even strong Phase 2 signals often fail to replicate in larger, more diverse Phase 3 populations. The interim analysis was based on only 50 subjects — a small subset of the planned trial — and while the EASI-50 and EASI-90 responses are encouraging, they lack the statistical power and durability data needed to confidently predict Phase 3 outcomes, especially in a disease as heterogeneous as atopic dermatitis where placebo response rates can be high and transient improvements common.
The company’s reliance on a novel mechanism — upstream modulation of epithelial danger sensing and cytokine signaling via polyhexanide — introduces significant regulatory and scientific uncertainty, as there are no approved topical therapies with this exact mechanism of action, meaning the FDA may require extensive mechanistic data, long-term safety studies, or additional clinical validation beyond what is currently planned, potentially delaying approval or requiring a larger trial footprint than anticipated. Unlike biologics targeting specific cytokines (e.g., dupilumab), GX-03’s broad upstream effects could raise questions about off-target effects on skin microbiome or barrier function over time, and the lack of precedent may lead to prolonged regulatory scrutiny, especially if the agency classifies it as a combination product or requests additional non-clinical toxicology data.
While the expansion into an intranasal influenza vaccine leverages Turn’s PermaFusion® platform, this represents a significant strategic shift into a highly competitive and capital-intensive vaccine market where success depends not only on preclinical data but on complex manufacturing, cold chain logistics (despite claims of thermostability), and proven immunogenicity in humans — none of which have been demonstrated yet, and the company has no prior experience in vaccine development or regulatory pathways for infectious disease candidates. The vaccine space is littered with failures from companies that overestimated platform transferability, and without partnerships with established vaccinologists or BARDA engagement, this initiative may consume valuable R&D resources without generating near-term value, diverting focus from the core GX-03 program at a critical juncture.
The Medline partnership, while promising for future wound care revenue, remains contingent on successful product development, regulatory clearance for PermaFusion® in wound indications, and commercial adoption — none of which are guaranteed, and the company has not yet disclosed any preclinical or clinical data supporting PermaFusion®’s efficacy in wound healing, infection control, or exudate management, meaning the near-term revenue expectations for late 2026 are highly speculative. Wound care is a crowded market with entrenched players and stringent reimbursement hurdles, and without demonstrated clinical superiority or cost-saving data, Turn may struggle to gain traction even if the product clears regulatory bars, making the revenue timeline uncertain and potentially delayed beyond current guidance.
Turn Therapeutics’ financials reveal a structural imbalance: operating expenses are heavily weighted toward general and administrative costs ($5.6 million in 2025 vs. $265,000 in R&D), suggesting that a disproportionate amount of capital is being spent on infrastructure, investor relations, and corporate overhead rather than direct therapeutic development, which could slow clinical progress despite the cash runway extensions. This imbalance, combined with a net loss that widened from $1.8 million in 2024 to $3.2 million in 2025 — driven largely by a quadrupling of G&A expenses — indicates that scaling as a public company may be consuming resources at a rate that undermines the efficiency of its R&D spend, raising concerns about whether the company can maintain fiscal discipline while advancing multiple pipelines simultaneously.

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password